{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:51:18Z","timestamp":1789717878876,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,8,12]],"date-time":"2012-08-12T00:00:00Z","timestamp":1344729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s11908-012-0287-z","type":"journal-article","created":{"date-parts":[[2012,8,11]],"date-time":"2012-08-11T15:35:15Z","timestamp":1344699315000},"page":"522-529","source":"Crossref","is-referenced-by-count":7,"title":["Immunoglobulins in Adult Sepsis and Septic Shock"],"prefix":"10.1007","volume":"14","author":[{"given":"Susanne","family":"Toussaint","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herwig","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,12]]},"reference":[{"key":"287_CR1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11908-007-0058-4","volume":"9","author":"H Gerlach","year":"2007","unstructured":"Gerlach H, Toussaint S. Organ failure in sepsis. Curr Infect Dis Rep. 2007;9:374\u201381.","journal-title":"Curr Infect Dis Rep"},{"key":"287_CR2","doi-asserted-by":"crossref","unstructured":"\u2022 Engel C, Brunkhorst FM, Bone H-G, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007;33:606\u201318. Excellent study with a randomized design to exclude biases such as hospital size, seasonal variations etc.","DOI":"10.1007\/s00134-006-0517-7"},{"key":"287_CR3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00134-006-0504-z","volume":"33","author":"S Karlsson","year":"2007","unstructured":"Karlsson S, Varpula M, Roukonen E, et al. Incidence, treatment and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med. 2007;33:435\u201343.","journal-title":"Intensive Care Med"},{"key":"287_CR4","unstructured":"EMEA Committee For Proprietary Medicinal Products: note for guidance on plasma-derived medicinal products. CPMP\/BPWG\/269\/95. Ser. 2, London, 1998."},{"key":"287_CR5","unstructured":"Europ\u00e4isches Arzneibuch, Monograph No. 918: \u201cHuman Immunoglobulins for intravenous application\u201d. Edited by Govi Publisher, Eschborn, Germany, 3rd Edition, 1997."},{"key":"287_CR6","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/blood.V95.8.2523","volume":"95","author":"A Gaines","year":"2000","unstructured":"Gaines A, Varricchio F, Kapit R. Renal insufficiency and failure associated with globulin intravenous administration in immune thrombocytopenic purpura patients. Blood. 2000;95:2523\u20139.","journal-title":"Blood"},{"key":"287_CR7","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1172\/JCI116240","volume":"91","author":"S Takei","year":"1993","unstructured":"Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest. 1993;91:602\u20137.","journal-title":"J Clin Invest"},{"key":"287_CR8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJM199201093260206","volume":"326","author":"JM Dwyer","year":"1992","unstructured":"Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med. 1992;326:107\u201316.","journal-title":"N Engl J Med"},{"key":"287_CR9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1086\/514588","volume":"26","author":"A Norrby-Teglund","year":"1998","unstructured":"Norrby-Teglund A, Basma H, Andersson J, et al. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis. 1998;26:631\u20139.","journal-title":"Clin Infect Dis"},{"key":"287_CR10","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/381979","volume":"38","author":"J Darenberg","year":"2004","unstructured":"Darenberg J, S\u00f6derquist B, Normark BH, Norrby-Teglund A. Differences in Potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis. 2004;38:836\u201342.","journal-title":"Clin Infect Dis"},{"key":"287_CR11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1086\/507037","volume":"43","author":"B Schrage","year":"2006","unstructured":"\u2022 Schrage B, Duan G, Yang LP, Fraser JD, Proft T. Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. Clin Infect Dis. 2006;43:743\u20136. Systematic analysis of the quality of different ivIG preparations demonstrating the potential impact on the design and outcome of clinical trials..","journal-title":"Clin Infect Dis"},{"key":"287_CR12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1086\/514585","volume":"26","author":"DL Stevens","year":"1998","unstructured":"Stevens DL. Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome. Clin Infect Dis. 1998;26:639\u201341.","journal-title":"Clin Infect Dis"},{"key":"287_CR13","first-page":"318","volume":"1","author":"D Gitlin","year":"1956","unstructured":"Gitlin D, Janeway CA. Agammaglobulinemia: congenital, acquired and transient forms. Prog Hematol. 1956;1:318\u201329.","journal-title":"Prog Hematol"},{"key":"287_CR14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1056\/NEJM195901082600206","volume":"260","author":"D Gitlin","year":"1959","unstructured":"Gitlin D, Gross PA, Janeway CA. The gamma globulins and their clinical significance. II. Hypogammaglobulinemia. N Engl J Med. 1959;260:72\u20136.","journal-title":"N Engl J Med"},{"key":"287_CR15","first-page":"81","volume":"36","author":"P Imbach","year":"1981","unstructured":"Imbach P, Barandun S, Baumgartner C, et al. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta. 1981;36:81\u20136.","journal-title":"Helv Paediatr Acta"},{"key":"287_CR16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","volume":"345","author":"MD Kazatchkine","year":"2001","unstructured":"\u2022\u2022 Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747\u201355. First class review for readers that are interested in the broad field pathophysiology, pharmacodynamics, of clinical use of ivIG, especially in patients with inflammatory and autoimmune diseases..","journal-title":"N Engl J Med"},{"key":"287_CR17","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1007\/s10072-003-0081-7","volume":"24","author":"J Bayry","year":"2003","unstructured":"Bayry J, Thirion M, Misra N, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci. 2003;24:S217\u201321.","journal-title":"Neurol Sci"},{"issue":"Suppl. 1","key":"287_CR18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.2009.04022.x","volume":"158","author":"A Durandy","year":"2009","unstructured":"\u2022\u2022 Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins \u2013 understanding properties and mechanisms. Clin Exp Immunol. 2009;158 Suppl 1:2\u201313. Our favorite review on the complex pathways by which ivIG preparations exert immunomodulatory effects..","journal-title":"Clin Exp Immunol"},{"key":"287_CR19","doi-asserted-by":"crossref","first-page":"e1002071","DOI":"10.1371\/journal.ppat.1002071","volume":"7","author":"C Ramakrishna","year":"2011","unstructured":"Ramakrishna C, Newo ANS, Shen YW, Cantin E. Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis. PLoS Pathogen. 2011;7:e1002071.","journal-title":"PLoS Pathogen"},{"key":"287_CR20","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1016\/j.molimm.2008.07.012","volume":"45","author":"M Basta","year":"2008","unstructured":"Basta M. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol Immunol. 2008;45:4073\u20139.","journal-title":"Mol Immunol"},{"issue":"Suppl. 1","key":"287_CR21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2249.2009.04024.x","volume":"158","author":"HP Hartung","year":"2009","unstructured":"\u2022 Hartung HP, Mouthon L, Ahmed R, et al. Clinical applications of intravenous immunoglobulins (IVIg) \u2013 beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009;158 Suppl 1:23\u201333. Excellent review especially for readers from the area of neurology and congenital syndromes where ivIG preparations are part of standard therapy..","journal-title":"Clin Exp Immunol"},{"key":"287_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2005.02834.x","volume":"142","author":"S Jolles","year":"2005","unstructured":"Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142:1\u201311.","journal-title":"Clin Exp Immunol"},{"key":"287_CR23","first-page":"35","volume":"2","author":"KG Moiseeva","year":"1977","unstructured":"Moiseeva KG, Nikiforova TV, Kharitonova AI, Koz\u2019minykh LF, Pavlovskaia EN. Intravenous administration of immunoglobulins in young children with staphylococcal infections. Probl Gematol Pereliv Krovi. 1977;2:35\u20138.","journal-title":"Probl Gematol Pereliv Krovi"},{"key":"287_CR24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1423-0410.1981.tb00717.x","volume":"40","author":"L Lindquist","year":"1981","unstructured":"Lindquist L, Lundbergh P, Maasing R. Pepsin-treated human gamma globulin in bacterial infections. A randomized study in patients with septicaemia and pneumonia. Vox Sang. 1981;40:329\u201337.","journal-title":"Vox Sang"},{"key":"287_CR25","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/BF00273538","volume":"11","author":"W Glinz","year":"1985","unstructured":"Glinz W, Grob PJ, Nydegger UE, et al. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. A randomized, placebo-controlled study. Intensive Care Med. 1985;11:288\u201394.","journal-title":"Intensive Care Med"},{"key":"287_CR26","first-page":"69","volume":"97","author":"A Cometta","year":"1994","unstructured":"Cometta A, Baumgartner JD, Glauser MP. Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients. Clin Exp Immunol. 1994;97:69\u201372.","journal-title":"Clin Exp Immunol"},{"key":"287_CR27","first-page":"393","volume":"158","author":"KC Fang","year":"1993","unstructured":"Fang KC. Monoclonal antibodies to endotoxin in the management of sepsis. West J Med. 1993;158:393\u20139.","journal-title":"West J Med"},{"key":"287_CR28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJM199102143240701","volume":"324","author":"EJ Ziegler","year":"1991","unstructured":"\u2022\u2022 Ziegler EJ, Fisher Jr CJ, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin \u2013 a randomized, double-blind, placebo-controlled trial. N Engl J Med. 1991;324:429\u201336. Definitely a \u201cmilestone\u201d paper, although the results were disappointing. Readers will learn a lot!.","journal-title":"N Engl J Med"},{"key":"287_CR29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.CCM.0000045564.51812.3F","volume":"31","author":"TE Albertson","year":"2003","unstructured":"Albertson TE, Panacek EA, MacArthur RD, et al. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis. Crit Care Med. 2003;31:419\u201327.","journal-title":"Crit Care Med"},{"key":"287_CR30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1378\/chest.102.2.613","volume":"102","author":"JW Christman","year":"1992","unstructured":"Christman JW. Potential treatment of sepsis syndrome with cytokine-specific agents. Chest. 1992;102:613\u20137.","journal-title":"Chest"},{"key":"287_CR31","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1378\/chest.103.3.932","volume":"103","author":"RC St John","year":"1993","unstructured":"St John RC, Dorinsky PM. Immunologic therapy for ARDS, septic shock, and multiple-organ failure. Chest. 1993;103:932\u201343.","journal-title":"Chest"},{"key":"287_CR32","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/00003246-200104000-00015","volume":"29","author":"K Reinhart","year":"2001","unstructured":"Reinhart K, Menges T, Gardlund B, et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med. 2001;29:765\u20139.","journal-title":"Crit Care Med"},{"key":"287_CR33","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00003246-199707000-00010","volume":"25","author":"SM Opal","year":"1997","unstructured":"Opal SM, Fisher Jr CJ, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med. 1997;25:1115\u201324.","journal-title":"Crit Care Med"},{"key":"287_CR34","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1086\/606048","volume":"49","author":"SS Shah","year":"2009","unstructured":"Shah SS, Hall M, Srivastava R, Subramony A, Levin JE. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis. 2009;49:1369\u201376.","journal-title":"Clin Infect Dis"},{"key":"287_CR35","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/515199","volume":"28","author":"R Kaul","year":"1999","unstructured":"Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome \u2013 a comparative observational study. Clin Infect Dis. 1999;28:800\u20137.","journal-title":"Clin Infect Dis"},{"key":"287_CR36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1086\/376630","volume":"37","author":"J Darenberg","year":"2003","unstructured":"\u2022 Darenberg J, Ihendyane N, Sj\u00f6lin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37:333\u201340. The most important study on ivIG in streptococcal toxic shock syndrome, still being the base for recommendations for the use of ivIG in these patients..","journal-title":"Clin Infect Dis"},{"key":"287_CR37","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1086\/606049","volume":"49","author":"L Valiquette","year":"2009","unstructured":"Valiquette L, Low DE, McGeer AJ. Assessing the impact of intravenous immunoglobulin in the management of streptococcal toxic shock syndrome: a noble but difficult question. Clin Infect Dis. 2009;49:1377\u20139.","journal-title":"Clin Infect Dis"},{"key":"287_CR38","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1086\/339549","volume":"34","author":"JL Vincent","year":"2002","unstructured":"Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis. 2002;34:1084\u201393.","journal-title":"Clin Infect Dis"},{"key":"287_CR39","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-2002-24252","volume":"127","author":"F Bloos","year":"2002","unstructured":"Bloos F, Reinhart K. New treatment approaches in sepsis. Zentralbl Chir. 2002;127:174\u20139.","journal-title":"Zentralbl Chir"},{"key":"287_CR40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1155\/2002\/127953","volume":"13","author":"KB Laupland","year":"2002","unstructured":"Laupland KB. Polyclonal intravenous immunoglobulin for the treatment of infection in critically ill patients. Can J Infect Dis. 2002;13:100\u20136.","journal-title":"Can J Infect Dis"},{"key":"287_CR41","doi-asserted-by":"crossref","unstructured":"Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev. 2002;1:CD001090. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11869591 . Accessed 6 August 2012.","DOI":"10.1002\/14651858.CD001090"},{"key":"287_CR42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1086\/421089","volume":"39","author":"J Pildal","year":"2004","unstructured":"Pildal J, Gotzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis. 2004;39:38\u201346.","journal-title":"Clin Infect Dis"},{"key":"287_CR43","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2796.2006.01726.x","volume":"260","author":"A Norrby-Teglund","year":"2006","unstructured":"Norrby-Teglund A, Haque KN, Hammarstrom L. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis. J Intern Med. 2006;260:509\u201316.","journal-title":"J Intern Med"},{"key":"287_CR44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.7326\/0003-4819-146-3-200702060-00009","volume":"146","author":"AF Turgeon","year":"2007","unstructured":"Turgeon AF, Hutton B, Fergusson DA, et al. Metaanalysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med. 2007;146:193\u2013203.","journal-title":"Ann Intern Med"},{"key":"287_CR45","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1097\/01.CCM.0000295312.13466.1C","volume":"35","author":"KB Laupland","year":"2007","unstructured":"\u2022 Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med. 2007;35:2686\u201392. Although all of the meta-analyses from Ref. 41 to Ref. 48 are important, this one was performed in a sound matter..","journal-title":"Crit Care Med"},{"key":"287_CR46","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1097\/01.CCM.0000295263.12774.97","volume":"35","author":"KG Kreymann","year":"2007","unstructured":"Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007;35:2677\u201385.","journal-title":"Crit Care Med"},{"key":"287_CR47","doi-asserted-by":"crossref","unstructured":"\u2022 Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock (review). Cochrane Library. 2010; doi: 10.1002\/14651858.CD001090 . Together with Ref. 41, this review is the confirming analysis for the limited evidence on the use of ivIG in adult patients with sepsis.","DOI":"10.1002\/14651858.CD001090"},{"key":"287_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16070","volume":"16","author":"MO Soares","year":"2012","unstructured":"\u2022\u2022 Soares MO, Welton NJ, Harrison DA, et al. An evaluation of the feasibility, cost and value of information of a multicenter randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technol Assess. 2012;16:1\u2013186. Definitely a \u201cmust\u201d for everybody who wants sufficient information on this topic. Many sub-analyses, many graphs, something like a \u201chandbook\u201d for EBM in severe sepsis..","journal-title":"Health Technol Assess"},{"key":"287_CR49","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1097\/01.CCM.0000295426.37471.79","volume":"35","author":"K Werdan","year":"2007","unstructured":"\u2022\u2022 Werdan K, Pilz G, Bujdoso O, et al. Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study. Crit Care Med. 2007;35:2693\u2013701. The most important RCT on ivIG in adult patients with severe sepsis..","journal-title":"Crit Care Med"},{"key":"287_CR50","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1100441","volume":"365","author":"P Brocklehurst","year":"2011","unstructured":"\u2022 Brocklehurst P, Farrell B, King A, for the INIS Collaborative Group, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med. 2011;365:1201\u201311. Extremely important, large RCT, although limited to very low weight newborns..","journal-title":"N Engl J Med"},{"key":"287_CR51","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF00918802","volume":"11","author":"ER Burns","year":"1991","unstructured":"Burns ER, Lee V, Rubinstein A. Treatment of septic thrombocytopenia with immune globulin. J Clin Immunol. 1991;11:363\u20138.","journal-title":"J Clin Immunol"},{"key":"287_CR52","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/01.CCM.0000215452.84291.C6","volume":"34","author":"M Hentrich","year":"2006","unstructured":"\u2022 Hentrich M, Fehnle K, Ostermann H, et al. IgM-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: a randomized, controlled, multiple-center trial. Crit Care Med. 2006;34:1319\u201325. The only available, good quality trial on the use of IgM-enriched ivIG in adult septic patients..","journal-title":"Crit Care Med"},{"key":"287_CR53","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.shk.0000157302.69125.f8","volume":"23","author":"A Rodriguez","year":"2005","unstructured":"Rodriguez A, Rello J, Neira J, et al. Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock. 2005;23:298\u2013304.","journal-title":"Shock"},{"key":"287_CR54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jama.279.4.281","volume":"279","author":"JP Ioannidis","year":"1998","unstructured":"Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA. 1998;279:281\u20136.","journal-title":"JAMA"},{"issue":"Suppl","key":"287_CR55","first-page":"15","volume":"9","author":"K Dickersin","year":"1997","unstructured":"Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ Prev. 1997;9(Suppl):15\u201321.","journal-title":"AIDS Educ Prev"},{"key":"287_CR56","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1378\/chest.127.1.242","volume":"127","author":"S Trzeciak","year":"2005","unstructured":"Trzeciak S, Zanotti-Cavazzoni S, Parrillo JE, Dellinger RP. Inclusion criteria for clinical trials in sepsis: did the American College of Chest Physicians\/Society of Critical Care Medicine consensus conference definitions of sepsis have an impact? Chest. 2005;127:242\u20135.","journal-title":"Chest"},{"key":"287_CR57","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/00003246-199109000-00003","volume":"19","author":"I Schedel","year":"1991","unstructured":"Schedel I, Dreikhausen U, Nentwig B, et al. Treatment of Gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med. 1991;19:1104\u201313.","journal-title":"Crit Care Med"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-012-0287-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11908-012-0287-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-012-0287-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T13:51:49Z","timestamp":1594561909000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11908-012-0287-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,12]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["287"],"URL":"https:\/\/doi.org\/10.1007\/s11908-012-0287-z","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"value":"1523-3847","type":"print"},{"value":"1534-3146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,12]]}}}